Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$102.28 USD
-2.40 (-2.29%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.28 USD
-2.40 (-2.29%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.
Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.
STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
by Zacks Equity Research
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.
ZBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.
Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.